# A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque Psoriasis

> **NCT03997786** · PHASE2,PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Sun Pharmaceutical Industries Limited** · enrollment: 135 (actual)

## Conditions studied

- Moderate-to-severe Chronic Plaque Psoriasis

## Interventions

- **DRUG:** Tildrakizumab
- **DRUG:** Placebo
- **DRUG:** Tildrakizumab
- **DRUG:** Tildrakizumab
- **DRUG:** Tildrakizumab
- **DRUG:** Etanercept
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03997786
- **Lead sponsor:** Sun Pharmaceutical Industries Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-01-15
- **Primary completion:** 2025-04-07
- **Final completion:** 2031-08-05
- **Target enrollment:** 135 (ACTUAL)
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03997786

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03997786, "A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque Psoriasis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03997786. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*